Black Rock Inc. Cardiff Oncology, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 677,458 shares of CRDF stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

677,458

Previous 716,490 5.45%

Holding current value

$1.5 Million

Previous $1.06 Million 241.23%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.46 - $5.91 $56,986 - $230,679	-39,032 Reduced 5.45%	677,458 $3.62 Million
Q4 2023 Feb 13, 2024	SELL	$0.96 - $1.55 $1,056 - $1,706	-1,101 Reduced 0.15%	716,490 $1.06 Million
Q3 2023 Nov 13, 2023	SELL	$1.38 - $2.18 $58,899 - $93,044	-42,681 Reduced 5.61%	717,591 $997,000
Q2 2023 Aug 11, 2023	BUY	$1.37 - $1.95 $3,361 - $4,785	2,454 Added 0.32%	760,272 $1.12 Million
Q1 2023 May 12, 2023	BUY	$1.45 - $2.09 $11,559 - $16,661	7,972 Added 1.06%	757,818 $1.25 Million

Q4 2022 Feb 13, 2023	BUY	$1.22 - $1.59 $912 - $1,189	748 Added 0.1%	749,846 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$1.57 - $3.21 $121,095 - $247,590	77,131 Added 11.48%	749,098 $1.15 Million
Q2 2022 Aug 12, 2022	SELL	$1.17 - $2.61 $2.13 Million - $4.76 Million	-1,824,153 Reduced 73.08%	671,967 $1.48 Million
Q1 2022 May 12, 2022	SELL	$2.11 - $7.25 $76,230 - $261,928	-36,128 Reduced 1.43%	2,496,120 $6.19 Million
Q4 2021 Feb 10, 2022	BUY	$5.18 - $7.24 $748,510 - $1.05 Million	144,500 Added 6.05%	2,532,248 $15.2 Million
Q3 2021 Nov 09, 2021	BUY	$5.01 - $7.58 $139,102 - $210,458	27,765 Added 1.18%	2,387,748 $15.9 Million
Q2 2021 Aug 11, 2021	BUY	$6.65 - $10.04 $15.7 Million - $23.7 Million	2,359,983 New	2,359,983 $15.7 Million

Others Institutions Holding CRDF

# of Institutions

Shares Held

8.48M

Call Options Held

798K

Put Options Held

39.2K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $96.2M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account